Unravel Biosciences and PECET Announce Collaboration to Conduct Clinical Trials of RVL-001 in Rett Syndrome and Pitt Hopkins Syndrome in Colombia | PR Newswire [Video]

Study site selection and finalization of clinical trial agreement final step toward initiation of RVL-001 proof-of-concept clinical studies early next year

, /PRNewswire/ — Unravel Biosciences, Inc., (“Unravel”), an AI-enabled therapeutics company established to advance drugs for complex diseases, andand the clinical research unit of the PECET of the University of Antioquia, certified in Good Clinical Practices by the Colombian Health Regulatory Authority (“INVIMA”) and located in in Medellín, Colombia, today announced the finalization of a clinical trial agreement enabling PECET to be the designated study site for Unravel’s RVL-001 proof of concept clinical trials for Rett syndrome (RTT) and Pitt Hopkins syndrome (PTHS) .

Unravel’s proprietary BioNAV™ drug discovery platform identified RVL-001 as a potentially promising therapeutic drug for Rett Syndrome and PTHS.   Building on previously announced initiatives by Unravel to initiate a proof-of-concept clinical trials of RVL-001 in Colombiafor RTT as well as a collaboration by the Pitt Hopkins Research …